Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Understanding the cellular and molecular basis of Chimeric Antigen Receptor T-cell therapy resistance

FY 2019-20

Summary
Chimeric Antigen Receptor (CAR) T-cell therapy has been a major breakthrough in cancer therapy, and recent clinical trials indicate that it is a potentially life-saving option for the most common form of pediatric leukemia. These clinical trials highlight one of the key questions in the field: why is this form of therapy so effective in some patients, yet ineffective in others? We hypothesize that early treatment failure to CAR T-cell therapy can be predicted by cellular pathways within the patient's T-cells, whereas treatment failure after initial response can be attributed to the clonal evolution of therapy-resistant cancer cells. To address this clinical challenge, we will use a systems immunology approach, leveraging modern high-throughput molecular assays on tumor and immune cells. We have collected T-cells from 71 patients prior to receiving CAR T-cell therapy and performed whole-transcriptome RNA-sequencing on their T-cell subtypes, providing a rich resource of gene expression profiles across patients. Using this data, we will develop a comprehensive atlas of T-cell pathways in therapy-responsive and therapy-resistant patients, allowing us to pinpoint the cellular pathways within these immune cells that allow for effective CAR T-cell therapy. In order to interrogate the mechanism of tumor evasion of CAR T-cell therapy, we have acquired tumor cells from patients prior to CAR T-cell therapy and at the time of relapse. Using whole-exome sequencing, RNA-Sequencing, and ultra-deep targeted Duplex sequencing, we will characterize the changes that occur within the tumor genomes and gene regulation that allow tumor cells to evade immune killing by CAR T-cells. Together, our approach will provide a comprehensive portrait of T-cell and tumor cell contributors to therapy response, and will inform the improvement of future cancer immunotherapies.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
Pennsylvania, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
415410
Name
Chen Gregory M
Region
Pennsylvania
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Understanding the cellular and molecular basis of Chimeric Antigen Receptor T-cell therapy resistance
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Bioinformatics; Cancer Immunotherapy; Immunology; Systems Biology
Abstract
Chimeric Antigen Receptor (CAR) T-cell therapy has been a major breakthrough in cancer therapy, and recent clinical trials indicate that it is a potentially life-saving option for the most common form of pediatric leukemia. These clinical trials highlight one of the key questions in the field: why is this form of therapy so effective in some patients, yet ineffective in others? We hypothesize that early treatment failure to CAR T-cell therapy can be predicted by cellular pathways within the patient's T-cells, whereas treatment failure after initial response can be attributed to the clonal evolution of therapy-resistant cancer cells. To address this clinical challenge, we will use a systems immunology approach, leveraging modern high-throughput molecular assays on tumor and immune cells. We have collected T-cells from 71 patients prior to receiving CAR T-cell therapy and performed whole-transcriptome RNA-sequencing on their T-cell subtypes, providing a rich resource of gene expression profiles across patients. Using this data, we will develop a comprehensive atlas of T-cell pathways in therapy-responsive and therapy-resistant patients, allowing us to pinpoint the cellular pathways within these immune cells that allow for effective CAR T-cell therapy. In order to interrogate the mechanism of tumor evasion of CAR T-cell therapy, we have acquired tumor cells from patients prior to CAR T-cell therapy and at the time of relapse. Using whole-exome sequencing, RNA-Sequencing, and ultra-deep targeted Duplex sequencing, we will characterize the changes that occur within the tumor genomes and gene regulation that allow tumor cells to evade immune killing by CAR T-cells. Together, our approach will provide a comprehensive portrait of T-cell and tumor cell contributors to therapy response, and will inform the improvement of future cancer immunotherapies.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chen, Gregory M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2019-20) | Canada Spends